Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image

Perspective - (2023) Volume 15, Issue 1

Discovering the Impact of New sedative Insomnia Pharmacologic Treatment with Edluar
William Simonson*
 
Department of Emergency Medicine, University of Toronto Mississauga, Mississauga, Canada
 
*Correspondence: William Simonson, Department of Emergency Medicine, University of Toronto Mississauga, Mississauga, Canada, Email:

Received: 25-Jan-2023, Manuscript No. JBB-23-20835; Editor assigned: 30-Jan-2023, Pre QC No. JBB-23-20835 (PQ); Reviewed: 13-Feb-2023, QC No. JBB-23-20835; Revised: 20-Feb-2023, Manuscript No. JBB-23-20835 (R); Published: 27-Feb-2023, DOI: 10.35248/0975-0851.23.15.504

Description

Edluar is a brand name for the prescription medication Zolpidem Tartrate, a short-acting sedative-hypnotic agent used to treat insomnia. It belongs to a class of drugs known as nonbenzodiazepine hypnotics, which work by enhancing the effects of Gamma-Aminobutyric Acid (GABA), a neurotransmitter that inhibits brain activity. Edluar is available in sublingual tablets that dissolve under the tongue, and it is typically taken just before bedtime. The drug is approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty falling asleep or staying asleep. Edluar is a Schedule IV controlled substance. It has a low potential for abuse and dependence compared to other sedative-hypnotics, such as benzodiazepines. However, like all medications in its class, Edluar can cause drowsiness and impaired cognitive function, and it should only be used under the guidance of a healthcare professional. Edluar is primarily used to treat insomnia, a sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early. Insomnia can have a significant impact on a person's quality of life, causing fatigue, irritability, difficulty concentrating, and other symptoms. Edluar is designed for short-term use, typically no more than 7 to 10 days. It is not intended to be used as a long-term solution for insomnia, as prolonged use can lead to dependence and tolerance, and higher doses are required to achieve the same effect.

Edluar is available in sublingual tablets of 5 mg and 10 mg strength. The recommended starting dose is 5 mg. The tablet should be placed under the tongue and allowed to dissolve completely. It should not be swallowed whole, chewed, or crushed. Edluar should be taken on an empty stomach, as food can delay the onset of action. Like all medications, Edluar can cause side effects, although not everyone who takes the drug will experience them. The most common side effects of Edluar include drowsiness, headache, dizziness, nausea, dry mouth, and fatigue, diarrhea, and abdominal discomfort. Less common but more serious side effects of Edluar include sleepwalking, sleep-driving, memory loss, hallucinations, mood changes, and suicidal thoughts. People who experience any of these side effects should stop taking Edluar and contact their healthcare provider immediately. These risks may be increased in older adults or those with certain medical conditions.

Edluar can interact with other medications, including prescription drugs, over-the-counter medicines, and herbal supplements. These interactions can affect how Edluar works or increase the risk of side effects. Some of the drugs that can interact with Edluar include Sedative-hypnotics, such as benzodiazepines, barbiturates, and opioids, Antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs), Antipsychotics, such as haloperidol and chlorpromazine, Muscle relaxants, such as cyclobenzaprine and carisoprodol.

While Edluar can be an effective treatment for sleep disorders, it also comes with potential benefits and risks. Edluar is designed to dissolve quickly in the mouth, allowing for faster absorption into the bloodstream. This means that it can work quickly to induce sleep and may be a good option for those who struggle to fall asleep quickly. Edluar has a relatively short half-life, which means that it is quickly eliminated from the body. This can be an advantage for those who have difficulty staying asleep throughout the night, as it can reduce the risk of residual sedation or drowsiness in the morning. Edluar comes in the form of a sublingual tablet that can be placed under the tongue and allowed to dissolve. This makes it a convenient and discreet option for those who need to take medication to help them sleep.

Like other sedative-hypnotics, Edluar has the potential to cause dependence and withdrawal symptoms when used for prolonged periods or at high doses. This can make it difficult to stop using the medication and may require a gradual tapering-off process to avoid withdrawal symptoms such as rebound insomnia, anxiety, and agitation. Edluar can interact with other medications, including other sedatives, antidepressants, and antipsychotics, which can increase the risk of adverse effects or overdose. It should not be used in combination with alcohol or other central nervous system depressants. It is important to use Edluar as directed by a healthcare provider and to weigh the benefits and risks of this medication before starting treatment.

Citation: Simonson W (2023) Discovering the Impact of New Sedative Insomnia Pharmacologic Treatment with Edluar. J Bioequiv Availab. 15:504.

Copyright: © 2023 Simonson W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.